These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27823655)

  • 21. Immune pathology of myelodysplastic syndromes.
    Tomonaga M
    Intern Med; 2001 Oct; 40(10):985-6. PubMed ID: 11688840
    [No Abstract]   [Full Text] [Related]  

  • 22. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
    Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
    Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Saif MW; Hopkins JL; Gore SD
    Leuk Lymphoma; 2002 Nov; 43(11):2083-92. PubMed ID: 12533032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Application of cyclosporine A in myelodysplastic syndrome--review].
    Guan M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):678-80. PubMed ID: 14706160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recent advances in the treatment of myelodysplastic syndromes].
    Gelsi-Boyer V; Vey N
    Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
    Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ
    Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging immunosuppressive drugs in myelodysplastic syndromes.
    Epling-Burnette PK; McDaniel J; Wei S; List AF
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):519-41. PubMed ID: 23163589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological abnormalities in myelodysplastic syndromes.
    Hamblin TJ
    Semin Hematol; 1996 Apr; 33(2):150-62. PubMed ID: 8722685
    [No Abstract]   [Full Text] [Related]  

  • 29. Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature.
    Erden A; Bilgin E; Kılıç L; Sarı A; Armağan B; Büyükaşık Y; Kalyoncu U
    Drug Metab Pers Ther; 2018 Jun; 33(2):105-108. PubMed ID: 29715182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.
    Chamuleau ME; Westers TM; van Dreunen L; Groenland J; Zevenbergen A; Eeltink CM; Ossenkoppele GJ; van de Loosdrecht AA
    Haematologica; 2009 Apr; 94(4):496-506. PubMed ID: 19229054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
    Kiladjian JJ; Visentin G; Viey E; Chevret S; Eclache V; Stirnemann J; Bourhis JH; Chouaib S; Fenaux P; Caignard A
    Haematologica; 2008 Mar; 93(3):381-9. PubMed ID: 18268282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune-induced cytopenia: bone marrow failure syndrome.
    Kondo Y; Molldrem JJ
    Curr Hematol Rep; 2004 May; 3(3):178-83. PubMed ID: 15087065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoimmune phenomena in patients with myelodysplastic syndromes.
    Enright H; Miller W
    Leuk Lymphoma; 1997 Feb; 24(5-6):483-9. PubMed ID: 9086438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Myelodysplastic syndromes and autoimmunity].
    Stalder G; Alberio L; Ribi C
    Rev Med Suisse; 2015 Apr; 11(469):820-2, 824-5. PubMed ID: 26040163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
    Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
    Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developmental therapeutics for myelodysplastic syndromes.
    Naing A; Sokol L; List AF
    J Natl Compr Canc Netw; 2006 Jan; 4(1):78-82. PubMed ID: 16403406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment.
    Barrett J; Sloand E; Young N
    Haematologica; 2006 May; 91(5):583-4. PubMed ID: 16670061
    [No Abstract]   [Full Text] [Related]  

  • 38. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myelodysplasia and autoimmunity.
    Giannouli S; Kanellopoulou T; Voulgarelis M
    Curr Opin Rheumatol; 2012 Jan; 24(1):97-102. PubMed ID: 22157417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating myelodysplastic syndromes.
    Ryan C; McCann S
    IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.